LWM
VRTX icon

Lionsbridge Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Lionsbridge Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-33
Closed -$7K – 308
2019
Q4 		$7K Buy
+33
New +$6.68K 0.01% 136

Other funds holding VRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lionsbridge Wealth Management's VRTX Position: Q1 2020 in Review

Lionsbridge Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2020, closing a stake of 33 shares — an estimated $7K sold.

Lionsbridge Wealth Management first reported a position in VRTX in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 856 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

  • Lionsbridge Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Lionsbridge Wealth Management sold 33 Vertex Pharmaceuticals shares in Q1 2020, an estimated $7K.
  • Lionsbridge Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Lionsbridge Wealth Management's Vertex Pharmaceuticals position peaked at $7K in Q4 2019.
  • 856 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Lionsbridge Wealth Management's 13F filing for Q1 2020, filed 29 Apr 2020.